Data / Research funding / Influenza
Influenza: 756 NIH awards ($1.9B) to 215 organizations
756 NIH awards ($1.9B) in the NIH spending category Influenza, to 215 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 756 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases: Mpox Clinical Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $150,331,625 | March 1, 2021 | February 28, 2026 | EWELL, MARIAN | reporter.nih.gov |
| NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: AVIAN INFLUENZA RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $91,354,067 | April 1, 2021 | January 14, 2027 | WEBBY, RICHARD | reporter.nih.gov |
| COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,825,966 | September 10, 2019 | September 24, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $62,580,113 | April 1, 2021 | September 17, 2026 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $53,879,677 | September 10, 2019 | September 9, 2026 | ROSS, TED | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $52,452,735 | September 10, 2019 | September 9, 2026 | MOODY, TONY | reporter.nih.gov |
| CEIRR: CORONAVIRUS RESEARCH ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $50,650,417 | April 1, 2021 | September 29, 2026 | HENSLEY, SCOTT | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component B: Vaccine Manufacturing and Toxicology Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,296,051 | August 26, 2019 | March 13, 2028 | DENNY, THOMAS | reporter.nih.gov |
| Vanderbilt Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $36,564,580 | December 11, 2019 | November 30, 2026 | CREECH, CLARENCE BUDDY | reporter.nih.gov |
| DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,010,720 | May 2, 2019 | April 30, 2027 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,250,171 | April 1, 2021 | January 14, 2027 | LOWEN, ANICE | reporter.nih.gov |
| Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,789,202 | May 15, 2019 | April 30, 2027 | STAAT, MARY A | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,280,590 | August 1, 2021 | January 14, 2027 | PEKOSZ, ANDREW | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,625,203 | April 1, 2021 | September 14, 2027 | TOMPKINS, S. MARK | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,720,676 | September 16, 2019 | September 15, 2026 | FRANKENFIELD, JILL | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,914,921 | September 16, 2019 | September 30, 2026 | BERES, WENDELL | reporter.nih.gov |
| NIAID Influenza Data Processing and Communication Center: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,386,477 | April 1, 2021 | March 31, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,884,300 | September 1, 2003 | April 30, 2029 | DAVIS, MARK MORRIS | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,115,898 | December 11, 2019 | November 30, 2026 | FRENCK, ROBERT WILSON | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| Advanced Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,853,574 | September 9, 2019 | April 24, 2025 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,234,165 | September 1, 2022 | January 1, 2027 | FELGNER, PHILIP | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Center for Modeling Complex Interactons | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $9,684,540 | March 15, 2015 | June 30, 2025 | WICHMAN, HOLLY A | reporter.nih.gov |
| Disordered Proteostasis as a Driver of Disease in the Aging Lung | NIH | National Institute on Aging | 2021 to 2024 | $8,161,610 | July 1, 2015 | March 31, 2025 | BUDINGER, GR SCOTT | reporter.nih.gov |
| A deep longitudinal analysis of next generation influenza vaccines in older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,127,184 | January 1, 2022 | December 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,400,390 | September 30, 2025 | September 29, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $7,281,050 | September 30, 2023 | September 29, 2028 | EL-KAMMASH, BRUXANNE | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| Emerging Infectious Diseases Research Center - East and Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,734,930 | June 1, 2020 | June 5, 2025 | NJENGA, M KARIUKI | reporter.nih.gov |
| Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,605,926 | December 9, 2021 | November 30, 2026 | LENG, SEAN XIAO | reporter.nih.gov |
| DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,359,752 | September 30, 2023 | September 29, 2028 | LAPEK, JENNIFER | reporter.nih.gov |
| DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,907,864 | September 30, 2023 | September 29, 2028 | BURKHART, DAVID | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Drivers of individual variation in influenza vaccine response and protection from infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,827,282 | July 14, 2022 | June 30, 2027 | COBEY, SARAH | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Task V02: Manufacture of Influenza for Human Challenge Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,587,695 | May 15, 2018 | May 31, 2026 | HASSEL, THOMAS | reporter.nih.gov |
| Advanced Development of Vaccines for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,495,941 | September 9, 2019 | May 31, 2027 | STAERZ, UWE | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| Development of vaccination strategies to elicit broadly protective immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,165,779 | June 18, 2019 | June 30, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,116,475 | June 9, 2023 | March 31, 2028 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,955,723 | September 11, 2020 | June 30, 2026 | COBEY, SARAH | reporter.nih.gov |
| Structure based design of trimer interface epitope focused universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,864,362 | March 12, 2020 | February 28, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,757,817 | November 22, 2021 | October 31, 2026 | MARASCO, WAYNE A. | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| Tissue factor-dependent coagulation in thrombosis and immune responses | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,577,076 | February 1, 2021 | January 31, 2028 | MACKMAN, NIGEL | reporter.nih.gov |
| Molecular Analysis and Lineage Tracing of Influenza-Specific, Lung-Resident Memory B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,398,832 | April 7, 2020 | March 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,300,145 | September 30, 2023 | September 29, 2026 | DOWLING, DAVID JAMES | reporter.nih.gov |
| Influenza pathogenesis in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,239 | June 14, 2021 | May 31, 2027 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,220,934 | September 25, 2017 | August 31, 2027 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Selecting HA glycosylation for improved vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,957,417 | June 9, 2021 | May 31, 2027 | ZAIA, JOSEPH | reporter.nih.gov |
| Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,950,305 | March 1, 2017 | July 31, 2025 | LIPKA, ELKE | reporter.nih.gov |
| Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,523 | August 20, 2021 | July 31, 2025 | AZOITEI, MIHAI LUCHIAN | reporter.nih.gov |
| Cellular and molecular programming of lung resident T cell memory | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,857,630 | May 1, 2020 | April 30, 2027 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Genetic Investigation of Covid 19 in Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,774,284 | August 1, 2022 | July 31, 2027 | KAHN, MARK L | reporter.nih.gov |
| Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,749,095 | August 1, 2021 | May 31, 2027 | LUSTIGMAN, SARA | reporter.nih.gov |
| Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,727,019 | September 24, 2021 | August 31, 2027 | JOST, STEPHANIE | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Flipped Germinal Centers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,701,340 | September 17, 2021 | August 31, 2026 | WESEMANN, DUANE R. | reporter.nih.gov |
| Novel mechanisms regulating immunity to respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,546,288 | August 2, 2023 | July 31, 2027 | PAUST, SILKE | reporter.nih.gov |
| Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,518,508 | February 16, 2021 | January 31, 2027 | KOHUT, MARIAN L | reporter.nih.gov |
| Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,479,164 | February 17, 2016 | April 30, 2027 | SURESH, MARULASIDDAPPA | reporter.nih.gov |
| Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,438,006 | April 23, 2021 | March 31, 2027 | TEYTON, LUC | reporter.nih.gov |
| Deciphering the relationship between structure, dynamics and function in helical bundle proteins | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,428,074 | May 1, 2017 | July 31, 2027 | DEGRADO, WILLIAM | reporter.nih.gov |
| Sex and Age Differences in Immunity to Influenza (SADII) | NIH | National Institute on Aging | 2021 to 2022 | $3,417,361 | September 30, 2018 | May 31, 2023 | KLEIN, SABRA L. | reporter.nih.gov |
| Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,407,387 | January 7, 2019 | December 31, 2023 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immunobiology of Influenza Virus-related Critical Illness in Young Hosts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,406,427 | September 18, 2020 | August 31, 2025 | RANDOLPH, ADRIENNE G | reporter.nih.gov |
| Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,375,497 | February 18, 2022 | January 31, 2027 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Inhalation Therapy Platform for Coronavirus Infection Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,373,230 | September 17, 2021 | August 31, 2026 | STAYTON, PATRICK S. | reporter.nih.gov |
| Developing Inhibitors of Seasonal and Pandemic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,352,410 | August 18, 2025 | July 31, 2029 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,332,208 | December 14, 2018 | November 30, 2024 | TING, JENNY P | reporter.nih.gov |
| Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,297,972 | April 2, 2021 | April 30, 2026 | RONG, LIJUN | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,620 | September 1, 2020 | June 30, 2025 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Hybrid Methods for Dynamic Structure Analysis of Proteins from Pathogenic Microorganisms | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,290,000 | July 1, 2021 | April 30, 2027 | MONTELIONE, GAETANO T | reporter.nih.gov |
| Programming Durable Immune Responses To Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,255,877 | December 18, 2018 | December 31, 2028 | ELLEBEDY, ALI HASSAN | reporter.nih.gov |
| Developing a bioprinted ventilated lung alveolar platform for investigating microbial interactions and influenza response | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,182,827 | August 19, 2025 | July 31, 2029 | OH, JULIA | reporter.nih.gov |
| Targeted Gene Delivery Systems Treating Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,172,072 | June 15, 2022 | May 31, 2026 | TIRRELL, MATTHEW | reporter.nih.gov |
| Development and optimization of a peptide inhibitor of influenza virus splicing for broad-spectrum antiviral therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,170,096 | August 1, 2025 | July 31, 2029 | TENOEVER, BENJAMIN R. | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Structural interrogation of vaccine- and infection-induced B cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,116,277 | February 22, 2022 | January 31, 2027 | BAJIC, GORAN | reporter.nih.gov |
| Universal room temperature stable influenza nanovaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,103,165 | January 24, 2019 | December 31, 2024 | NARASIMHAN, BALAJI | reporter.nih.gov |
| Uncovering latent factors underlying weak and robust responses to influenza vaccine in healthy and obese older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,095,170 | July 13, 2022 | June 30, 2027 | ALCORN, JOHN F | reporter.nih.gov |
| The role of cryptic influenza virus proteins in replication and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,085,097 | July 9, 2025 | June 30, 2029 | MEHLE, ANDREW | reporter.nih.gov |
| TCR-dependent and epigenetic mechanisms guiding influenza-specific CD4+ T cell responses in the lung | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,078,308 | August 1, 2025 | July 31, 2029 | HALE, JEFFREY SCOTT | reporter.nih.gov |
| Clonal Dynamics of the antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,017,736 | January 1, 2017 | December 31, 2026 | VICTORA, GABRIEL D | reporter.nih.gov |
| Universal Influenza A/B Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,998,889 | August 7, 2020 | April 30, 2026 | BAGLEY, KENNETH C | reporter.nih.gov |
| Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,998,175 | April 1, 2021 | March 31, 2026 | CHENG, SUSAN | reporter.nih.gov |
| Increasing Availability of Emulsion Adjuvants via Synthetic Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,996,311 | August 30, 2022 | August 29, 2025 | KEMPINSKI, CHASE | reporter.nih.gov |
| Innovations in Functional B Cell Epitope Discovery for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,991,588 | September 30, 2025 | September 29, 2026 | KELSOE, GARNETT | reporter.nih.gov |
| Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,964,030 | September 1, 2023 | August 31, 2026 | FRIZZELL, HANNAH | reporter.nih.gov |
| Kinase Regulation of Nuclear Speckle Function and Splicing during Influenza Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,940,532 | May 25, 2016 | August 31, 2026 | LYNCH, KRISTEN W | reporter.nih.gov |
| REDES: a peer network and mobile health (mHealth) enhanced CHW model to maximize COVID-19 vaccination among low income Latinos | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,925,112 | April 13, 2022 | October 31, 2027 | PAGE, KATHLEEN R | reporter.nih.gov |
| Mechanistic evaluation of the role of circadian rhythms in acute lung injury and subsequent recovery | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,922,801 | September 20, 2021 | August 31, 2027 | SENGUPTA, SHAON | reporter.nih.gov |
| Accelerating viral outbreak detection in US cities using mechanistic models, machine learning and diverse geospatial data | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,917,739 | February 24, 2020 | January 31, 2025 | GALVANI, ALISON P | reporter.nih.gov |
| Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,898,030 | February 10, 2022 | August 31, 2026 | CHAHAL, JASDAVE | reporter.nih.gov |
| Impact of repeated vaccination on the effectiveness of seasonal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,895,020 | March 3, 2020 | February 28, 2027 | WAN, XIUFENG HENRY | reporter.nih.gov |
| Evolution and Transmission of Influenza Virus in Natural Human Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,893,554 | July 2, 2020 | June 30, 2026 | LAURING, ADAM | reporter.nih.gov |
| Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $2,872,823 | April 23, 2021 | April 1, 2025 | BICKMORE, TIMOTHY W. | reporter.nih.gov |
| Task B1C1: Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation Natural History Challenge Study for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,862,138 | April 15, 2019 | November 30, 2024 | ORTIZ, JUSTIN | reporter.nih.gov |
| Tfh dysfunction in HIV and Aging | NIH | National Institute on Aging | 2021 to 2024 | $2,856,124 | September 30, 2020 | April 30, 2026 | PAHWA, SAVITA | reporter.nih.gov |
| Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,853,123 | January 8, 2019 | December 31, 2025 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Microarray Patch for Broadly Protective Seasonal Influenza Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,845,449 | April 9, 2021 | March 31, 2024 | KOSUDA, KATHRYN | reporter.nih.gov |
| Virtual Patient Cohorts to Illuminate Immunologic Drivers of Influenza Severity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,844,812 | June 1, 2022 | May 31, 2027 | SMITH, AMBER M | reporter.nih.gov |
| Molecular Mechanisms and In Vivo Impact of Tethered Mucin 1-Influenza Virus Interactions | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,842,330 | January 15, 2021 | December 31, 2026 | SCULL, MARGARET ADELE | reporter.nih.gov |
| Protective functions of influenza-specific lung-resident memory B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,821,316 | June 16, 2020 | May 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| Central role of Caspase-8 in control of host tolerance and resistance mechanisms in pulmonary macrophage populations during severe respiratory infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,808,365 | August 15, 2023 | May 31, 2027 | JAMIESON, AMANDA M | reporter.nih.gov |
| Mechanisms of regulatory T cell-mediated recovery from severe viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,783,450 | March 1, 2020 | June 30, 2029 | SINGER, BENJAMIN DAVID | reporter.nih.gov |
| RNA:protein interactions that dictate the success of influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,759,202 | February 2, 2022 | January 31, 2027 | MEHLE, ANDREW | reporter.nih.gov |
| Modeling the Coupled Dynamics of COVID-19 Transmission and Protective Behaviors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,758,288 | September 17, 2021 | August 31, 2027 | PARKER, ANDREW | reporter.nih.gov |
| Defining the Fc-correlates of protection against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,753,246 | March 11, 2020 | February 28, 2026 | LINGWOOD, DANIEL | reporter.nih.gov |
| High-throughput assays and small-molecule discovery of antiviral candidates targeting influenza hemagglutinin | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,727,483 | May 1, 2021 | April 30, 2026 | WILSON, IAN A | reporter.nih.gov |
| Innate immune signaling and stress response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,692,500 | March 15, 2016 | February 28, 2026 | KANNEGANTI, THIRUMALA-DEVI | reporter.nih.gov |
| Influenza Attenuates Innate Pulmonary Host Defense against Invasive Pulmonary Aspergillosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,690,414 | July 15, 2021 | June 30, 2027 | ROBINSON, KEVEN MARA | reporter.nih.gov |
| Syndecan-1 suppression of lung inflammation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,688,430 | April 25, 2022 | March 31, 2026 | CHEN, PETER | reporter.nih.gov |
| Protein therapy to treat virus induced cardiopulmonary injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,684,754 | June 6, 2022 | May 31, 2026 | MA, JIANJIE | reporter.nih.gov |
| Seasonal and universal Vaccination in aged populations with pre-existing immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,672,903 | May 21, 2021 | April 30, 2027 | KANG, SANG-MOO | reporter.nih.gov |
| Genetically modified pigs to model NKT cell immunity to influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,654,780 | April 6, 2022 | March 31, 2027 | DRIVER, JOHN | reporter.nih.gov |
| Quantifying Error Growth to Improve Infectious Disease Forecast Accuracy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,622,260 | June 9, 2021 | May 31, 2027 | SHAMAN, JEFFREY L | reporter.nih.gov |
| Balancing epithelial cell resistance and resilience to respiratory viral infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,621,215 | January 1, 2023 | December 31, 2027 | ORDOVAS-MONTANES, JOSE MANUEL | reporter.nih.gov |
| Pandemrix and T Cell Immunology in Narcolepsy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,607,677 | May 13, 2021 | April 30, 2025 | MIGNOT, EMMANUEL J | reporter.nih.gov |
| Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,605,499 | August 25, 2020 | May 31, 2023 | BILSEL, PAMUK | reporter.nih.gov |
| ETS-family Transcription Factor Mediated Control of Pulmonary Inflammation Induced by Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,590,407 | February 1, 2019 | October 31, 2028 | HEATON, NICHOLAS S | reporter.nih.gov |
| Targeted genetic engineering of B cells to induce protective antibody responses to viral pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,577,835 | July 5, 2022 | June 30, 2027 | ADAIR, JENNIFER EILEEN | reporter.nih.gov |
| Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,568,474 | June 1, 2020 | May 31, 2026 | WEAVER, ERIC A | reporter.nih.gov |
| VACCINE ADJUVANT DISCOVERY PROGRAM (VADP) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,547,484 | September 30, 2025 | September 29, 2026 | LEVY, OFER | reporter.nih.gov |
| Epitope focusing by molecular grafting of subdominant epitopes to achieve a universal-influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,528,765 | July 22, 2019 | June 30, 2024 | SCHMIDT, AARON GREGORY | reporter.nih.gov |
| Engineering Protein Antigens and their Presentation from Multivalent Scaffolds | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,480,883 | July 7, 2023 | June 30, 2028 | KANE, RAVI S. | reporter.nih.gov |
| Deciphering the Heterogeneous Response to Influenza by a Multi-Scale Systems Approach | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,480,693 | July 14, 2022 | June 30, 2027 | FORST, CHRISTIAN | reporter.nih.gov |
| Lung leukocytes promote alveolar epithelial regeneration after severe injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,469,157 | May 1, 2020 | April 30, 2026 | ARPAIA, NICHOLAS | reporter.nih.gov |
| Treatment of Inflammatory Complications of Respiratory Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,463,597 | June 20, 2022 | July 31, 2026 | LARK, MICHAEL WILLIAM | reporter.nih.gov |
| New mouse model to better predict human immunity to influenza vaccination and infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,461,120 | August 1, 2021 | July 31, 2025 | MASOPUST, DAVID | reporter.nih.gov |
| Modeling the development, structure and regulation of T cell memory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,452,681 | March 1, 2011 | August 31, 2026 | YATES, ANDREW | reporter.nih.gov |
| Dynamic regulatory network models of human response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,434,869 | August 17, 2020 | May 31, 2026 | MARAZZI, IVAN | reporter.nih.gov |
| Functional and genetic constraints on influenza virus replication and fidelity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,431,062 | June 17, 2022 | May 31, 2027 | LAURING, ADAM | reporter.nih.gov |
| Effects of obesity on the dynamics of Influenza transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,430,473 | June 10, 2019 | May 31, 2025 | SCHULTZ-CHERRY, STACEY L | reporter.nih.gov |
| Does repeated influenza vaccination constrain influenza immune responses and protection? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,405,849 | July 3, 2019 | June 30, 2025 | FOX, ANNETTE | reporter.nih.gov |
| Predictive fitness models for influenza vaccine strain selection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,404,863 | January 13, 2022 | August 10, 2025 | LUKSZA, MARTA | reporter.nih.gov |
| Structure and dynamics of RNA elements regulating viral aberrant RNA synthesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,396,295 | September 8, 2022 | August 31, 2027 | TE VELTHUIS, AREND JAN | reporter.nih.gov |
| Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,388,592 | September 21, 2016 | May 31, 2025 | CHAPMAN, HAROLD A | reporter.nih.gov |
| Using three-dimensional protein networks to uncover immuno-modulatory molecular phenotypes in infectious disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,378,125 | August 1, 2021 | July 31, 2027 | DAS, JISHNU | reporter.nih.gov |
| Fungal dysbiosis regulation of post-influenza bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,376,545 | July 16, 2021 | June 30, 2025 | CHEN, PETER | reporter.nih.gov |
| Improve Lung Regeneration Through Targeting Tuft Cells Following Viral Infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,371,262 | August 20, 2021 | June 30, 2026 | QUE, JIANWEN | reporter.nih.gov |
| Defining the Interplay Between Viral Adaptation and Host Proteostasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,362,578 | September 19, 2022 | July 31, 2027 | SHOULDERS, MATTHEW DONALD | reporter.nih.gov |
| Anticipating and rapidly responding to respiratory virus outbreaks with continuous air sampling in K-12 schools | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,338,302 | January 18, 2023 | December 31, 2027 | O'CONNOR, DAVID H. | reporter.nih.gov |
| Mechanisms of innate resistance to virus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,323,545 | February 1, 2017 | January 31, 2027 | YOUNT, JACOB | reporter.nih.gov |
| Multivalent nanocluster universal influenza vaccine given by microneedle patch | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,311,653 | February 12, 2019 | January 31, 2026 | WANG, BAOZHONG | reporter.nih.gov |
| Improving predictive capacity of models for universal influenza vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,303,623 | August 1, 2020 | July 31, 2025 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,299,720 | August 16, 2024 | January 31, 2027 | LIPKA, ELKE | reporter.nih.gov |
| Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,298,010 | April 25, 2022 | May 30, 2026 | COOPER, COLLEEN DOYLE | reporter.nih.gov |
| Identifying Influenza Virus Infection Severity and Outcome Signatures Through Artificial Intelligence-driven Analyses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,286,566 | July 7, 2022 | June 30, 2028 | DUPONT, CHRISTOPHER L. | reporter.nih.gov |
| Biology of Lymphangiogenesis in the Adult Lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,281,864 | July 1, 2022 | June 30, 2027 | JONES, MATTHEW ROBERT | reporter.nih.gov |
| Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,280,238 | November 14, 2022 | October 31, 2027 | LEGGE, KEVIN L | reporter.nih.gov |
| Syrian hamsters as an animal model for influenza virus research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,277,423 | September 2, 2020 | August 31, 2025 | KAWAOKA, YOSHIHIRO | reporter.nih.gov |
| Roles of tissue-resident helper T cells in mucosal immunity against influenzainfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,276,812 | February 1, 2022 | April 30, 2025 | SUN, JIE | reporter.nih.gov |
| Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,261,035 | January 15, 2020 | December 31, 2025 | AINSLIE, KRISTY M | reporter.nih.gov |
| Elucidating the roles of alveolar macrophage inflammation and self renewal during influenza infection | NIH | National Institute on Aging | 2021 to 2025 | $2,252,254 | August 15, 2020 | April 30, 2030 | SUN, JIE | reporter.nih.gov |
| Role of spatial structure in shaping viral population diversity and evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,238,488 | August 17, 2020 | July 31, 2025 | LOWEN, ANICE C | reporter.nih.gov |
| CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,227,740 | April 1, 2014 | August 1, 2022 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Universal T cell targeted influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,225,857 | September 1, 2020 | August 31, 2025 | HOFT, DANIEL F. | reporter.nih.gov |
| Targeting RIPK3 in Flu-Associated Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,222,961 | September 18, 2019 | August 31, 2025 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Functional Implications of Tfh Cell Heterogeneity after Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,219,856 | January 24, 2022 | December 31, 2026 | RANDALL, TROY D | reporter.nih.gov |
| The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,219,353 | May 15, 2020 | April 30, 2026 | JIA, HONGPENG | reporter.nih.gov |
| Interplay between influenza virus and S1P-metabolizing enzymes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,218,924 | June 10, 2021 | May 31, 2027 | HAHM, BUMSUK | reporter.nih.gov |
| Regulation of the interferon lamda receptor by influenza | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,215,117 | April 1, 2006 | June 30, 2026 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| Development of vaccine approaches to elicit broadly protective influenza-specific immune responses in infants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,208,932 | August 5, 2020 | July 31, 2026 | ALEXANDER-MILLER, MARTHA ANN | reporter.nih.gov |
| Loss of Endothelial S1PR1 Drives Post-Influenza Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,206,371 | June 15, 2023 | May 31, 2028 | KNIPE, RACHEL S | reporter.nih.gov |
| Identification and characterization of effector memory B cell populations that dominate memory responses to subsequent influenza infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,206,266 | August 3, 2020 | July 31, 2025 | LUND, FRANCES E. | reporter.nih.gov |
| Coordinated regeneration of lung epithelial and endothelial compartments | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,201,693 | August 20, 2022 | July 31, 2026 | VAUGHAN, ANDREW | reporter.nih.gov |
| Control of influenza virus induced type I interferon signaling during pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,200,686 | November 1, 2022 | October 31, 2027 | HEATON, NICHOLAS S | reporter.nih.gov |
| Forecasting influenza evolution on a heterogeneous immune landscape | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,197,907 | February 15, 2022 | January 31, 2028 | BEDFORD, TREVOR BC | reporter.nih.gov |
| Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,169,230 | June 1, 2022 | May 31, 2027 | BOONS, GEERT-JAN | reporter.nih.gov |
| Task A44: Ferret Models for the Evaluation of Universal Influenza Vaccines and Vaccine Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,150,482 | August 13, 2020 | May 9, 2022 | WALTERS, KEVIN | reporter.nih.gov |
| Dynamic regulatory network models of human response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,128,800 | August 17, 2020 | October 3, 2022 | MARAZZI, IVAN | reporter.nih.gov |
| Genetic Contributors to the Impact of Sex on Heterogeneity in Flu Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,125,850 | July 11, 2022 | June 30, 2027 | KO, DENNIS CHUN-YONE | reporter.nih.gov |
| Linking SARS-CoV-2 Aerosol Viability and Environmental Factors in Healthcare Settings | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,121,919 | August 17, 2023 | July 31, 2027 | KELLY, KERRY | reporter.nih.gov |
| Influenza & COVID Obstetric and Perinatal Epidemiology Study in India | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,121,321 | September 23, 2022 | August 31, 2027 | HIBBERD, PATRICIA L | reporter.nih.gov |
| mRNA-encoded Cas13 as a pan-respiratory antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,120,971 | January 23, 2023 | December 31, 2027 | SANTANGELO, PHILIP J | reporter.nih.gov |
| Alveolar responses to viral lung infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,088,426 | June 20, 2022 | May 31, 2027 | HOOK, JAIME LYNN | reporter.nih.gov |
| Biophysical studies of viral membrane fusion proteins | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,067,810 | July 1, 2022 | June 30, 2027 | MUNRO, JAMES B | reporter.nih.gov |
| Integrating measurements of immune escape and in vitro replication with computational models to understand and predict the antigenic evolution of seasonal A/H3N2 influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,056,935 | February 7, 2022 | January 31, 2027 | SMITH, DEREK JAMES | reporter.nih.gov |
| Regulation of the host immune response to influenza by the checkpoint receptor Tim3 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,054,835 | May 1, 2020 | April 30, 2026 | CHO, JOSALYN L | reporter.nih.gov |
| Influenza A Inhibits TH17 Host Defense Against Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,049,603 | January 1, 2012 | March 31, 2026 | ALCORN, JOHN F | reporter.nih.gov |
| Biophysical constraints of influenza neuraminidase evolution | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,049,096 | June 28, 2022 | May 31, 2027 | WU, NICHOLAS C. | reporter.nih.gov |
| Development of a Universal Influenza Vaccine Against Influenza A and B Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,044,468 | November 12, 2018 | October 31, 2024 | GILL, HARVINDER SINGH | reporter.nih.gov |
| Sequence-function relationship of influenza broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,039,386 | January 25, 2022 | December 31, 2026 | WU, NICHOLAS C. | reporter.nih.gov |
| Novel lung resident interstitial macrophage subset with distinct localization and polarization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,035,067 | January 1, 2019 | December 31, 2023 | KHANNA, KAMAL MOHAN | reporter.nih.gov |
| Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,019,810 | August 20, 2018 | March 31, 2024 | LINKE, LYNDSEY | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,018,199 | September 30, 2023 | September 29, 2026 | SORENSON, GREGORY | reporter.nih.gov |
| Consequences of Direct Viral-Bacterial Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,014,549 | January 5, 2022 | December 31, 2026 | ROSCH, JASON W. | reporter.nih.gov |
| Early Responses to Influenza A Virus Replication In Vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,004,034 | March 1, 2020 | February 28, 2026 | LANGLOIS, RYAN | reporter.nih.gov |
| Strain-Independent Therapeutic Antibodies for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,999,271 | July 1, 2014 | January 31, 2023 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Megakaryocyte regulation by the gut microbiome | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,980,652 | June 1, 2023 | March 31, 2027 | ZENG, MELODY Y | reporter.nih.gov |
| Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,972,366 | August 27, 2021 | July 31, 2026 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| Mechanism of Protein Synthesis and Translational Control | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,962,066 | June 1, 2021 | May 31, 2027 | JOSEPH, SIMPSON | reporter.nih.gov |
| Molecular regulation of protective CD8 immunity against influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,956,077 | February 10, 2015 | April 30, 2025 | SUN, JIE | reporter.nih.gov |
| Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,952,609 | July 1, 2022 | June 30, 2027 | COUGHLAN, LYNDA | reporter.nih.gov |
| Unraveling the Viral Infection Pathway with Virus-locked Observation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,947,117 | August 15, 2017 | May 31, 2027 | WELSHER, KEVIN | reporter.nih.gov |
| Role of preexisting immunity on airborne transmission of influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,945,314 | February 1, 2023 | January 31, 2027 | LAKDAWALA, SEEMA S. | reporter.nih.gov |
| Novel Influenza nano vaccines for broad cross protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,941,278 | May 15, 2012 | June 30, 2025 | WANG, BAOZHONG | reporter.nih.gov |
| Skin vaccination and generation of protective lung-tropic memory T cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,906,147 | December 18, 2023 | October 31, 2028 | KUPPER, THOMAS S. | reporter.nih.gov |
| Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,900,000 | September 22, 2021 | August 31, 2027 | STRUTT, TARA MARLENE | reporter.nih.gov |
| Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,899,426 | June 1, 2024 | May 31, 2027 | KUTSCHER, HILLIARD | reporter.nih.gov |
| Functional diversity of lung pericytes in lung injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,899,368 | December 15, 2022 | November 30, 2027 | HUNG, CHI F | reporter.nih.gov |
| PROmotion of COVid-19 VA(X)ccination in the Emergency Department - PROCOVAXED | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,899,293 | May 24, 2021 | March 10, 2025 | RODRIGUEZ, ROBERT | reporter.nih.gov |
| Elucidating the role of type I interferon signaling and macrophage-derived inflammation in the juvenile host with viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,898,753 | May 8, 2023 | February 28, 2027 | COATES, BRIA M | reporter.nih.gov |
| Control of antiviral memory CD8+ T cell longevity by extracellular ATP sensing | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,894,856 | July 1, 2022 | June 30, 2027 | BORGES DA SILVA, HENRIQUE | reporter.nih.gov |
| Harnessing type I interferon to promote lung-resident memory CD4 T cell immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,893,259 | June 21, 2022 | May 31, 2027 | MCKINSTRY, KARL KAI | reporter.nih.gov |
| Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,890,792 | June 1, 2023 | May 31, 2028 | WAGAR, LISA | reporter.nih.gov |
| A new mucosal adjuvant for augmenting influenza vaccines in elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,887,393 | May 24, 2021 | April 30, 2027 | WU, MEI X | reporter.nih.gov |
| Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,886,759 | August 23, 2016 | May 31, 2026 | BEDFORD, TREVOR BC | reporter.nih.gov |
| 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,881,701 | April 26, 2023 | March 31, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| Alpha(v) integrins and germinal center B cell responses to viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,880,880 | August 1, 2020 | July 31, 2024 | ACHARYA, MRIDU | reporter.nih.gov |
| Single cell molecular analysis of influenza vaccine responses in elderly individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,879,797 | March 1, 2019 | February 28, 2025 | KALAMS, SPYROS A | reporter.nih.gov |
| Markers and regulation of regulatory CD8+ T cells during influenza-induced lung immunopathology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,878,277 | July 1, 2021 | June 30, 2027 | HUANG, WEISHAN | reporter.nih.gov |
| Innate NLRC4 signaling controls adaptive immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,874,689 | June 20, 2023 | May 31, 2028 | SUTTERWALA, FAYYAZ S. | reporter.nih.gov |
| Context dependent amino acid availability and sensing determines humoral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,869,187 | February 10, 2022 | January 31, 2027 | ZENG, HU | reporter.nih.gov |
| Understanding and targeting fibroblast activation in influenza-triggered lung inflammation and post-viral disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,866,950 | September 1, 2023 | August 31, 2028 | BOYD, DAVID FIELDING | reporter.nih.gov |
| Targeting Influenza A Virus by a Carbohydrate-inspired Strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,866,200 | September 18, 2019 | December 31, 2027 | WONG, CHI-HUEY | reporter.nih.gov |
| Memory CD8 T cell localization and protection from influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,841,052 | November 1, 2014 | December 31, 2024 | HARTY, JOHN T | reporter.nih.gov |
| Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,837,793 | June 21, 2019 | May 31, 2024 | PARDI, NORBERT | reporter.nih.gov |
| Influenza virus receptors on human airway epithelial cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,818,983 | September 3, 2015 | July 31, 2025 | PAULSON, JAMES C | reporter.nih.gov |
| Addressing Vaccine AcceptaNce in Carceral Settings through Community Engagement (ADVANCE) | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $1,811,735 | September 26, 2022 | December 31, 2026 | PUGLISI, LISA BALZANO | reporter.nih.gov |
| Virulence Factor at the Interface of Viral and Cellular mRNA Nuclear Export | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,776,477 | May 6, 2020 | April 30, 2026 | FONTOURA, BEATRIZ MA | reporter.nih.gov |
| Regulation Of Lung Immunity By Antibody Glycosylation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,761,927 | February 13, 2024 | December 31, 2028 | WANG, TAIA | reporter.nih.gov |
| Mechanisms of dysregulated immunity with aging | NIH | National Institute on Aging | 2021 to 2023 | $1,757,769 | July 15, 2007 | December 31, 2024 | DENG, JANE C | reporter.nih.gov |
| Role of mitophagy in age-related respiratory and vascular diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,755,000 | January 1, 2021 | October 31, 2023 | GOLDSTEIN, DANIEL ROBERT | reporter.nih.gov |
| Adrenergic control of circadian rhythms in CD8 T cells responding to influenza | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,731,396 | July 1, 2023 | June 30, 2028 | FARRAR, JOHN DAVID | reporter.nih.gov |
| Leveraging community-based behavioral health to increase vaccine uptake in Latinx adults with mental illness | NIH | National Institute of Nursing Research | 2022 to 2024 | $1,714,097 | September 26, 2022 | March 10, 2025 | DAVISON, KIRSTEN | reporter.nih.gov |
| Vaccination responses in lung transplant recipients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,708,641 | August 5, 2022 | July 31, 2027 | NICOLLS, MARK ROBERT | reporter.nih.gov |
| A point-of-care device using Single Molecule Array (Simoa) to measure viral antigens in nasal swabs, saliva, and blood | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 | $1,705,157 | September 22, 2022 | August 31, 2025 | DUFFY, DAVID C | reporter.nih.gov |
| High-resolution single cell profiling of vaccine responsiveness in the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,687,224 | February 14, 2019 | January 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| A Flexible High-Throughput Immunological Assay to Support Next-Generation Influenza Vaccine Studies | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,679,190 | May 3, 2023 | April 30, 2026 | SIGAL, GEORGE B | reporter.nih.gov |
| Mechanisms of platelet reprogramming during influenza infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,675,000 | July 1, 2020 | June 30, 2025 | KOUPENOVA, MILKA | reporter.nih.gov |
| Text4Vax: Understanding the Implementation of Informational Text Messages for Pediatric Influenza Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,667,321 | April 15, 2024 | February 29, 2028 | STOCKWELL, MELISSA S | reporter.nih.gov |
| Use of Clinical Samples to Identify Influenza Virus Antigenic Variants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,659,372 | July 17, 2019 | June 30, 2025 | WAN, XIUFENG HENRY | reporter.nih.gov |
| PspA binds necroptotic cells to cause disease and transmit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,641,325 | September 24, 2020 | August 31, 2025 | ORIHUELA, CARLOS J | reporter.nih.gov |
| FcRn-Targeted Mucosal Vaccination Against Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,633,734 | May 14, 2019 | April 30, 2025 | ZHU, XIAOPING | reporter.nih.gov |
| BE IMMUNE: Behavioral Economics to Improve and Motivate vaccination Using Nudges through the EHR | NIH | National Institute on Aging | 2022 to 2024 | $1,628,541 | August 15, 2020 | August 31, 2025 | MEHTA, SHIVAN JATIN | reporter.nih.gov |
| Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,619,208 | January 16, 2018 | December 31, 2023 | FOX, CHRISTOPHER B | reporter.nih.gov |
| Understanding alterations to mucus composition and function in asthma | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,614,918 | July 1, 2022 | April 30, 2027 | DUNCAN, GREGG | reporter.nih.gov |
| Immunogenetics of COVID-19 Immune Response | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,614,396 | August 1, 2024 | July 31, 2029 | KENNEDY, RICHARD B | reporter.nih.gov |
| Solitary chemosensory / tuft cells in lung regeneration and inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,597,401 | June 1, 2020 | May 31, 2025 | VAUGHAN, ANDREW | reporter.nih.gov |
| The Role of Eicosanoid-PPAR axis in Exacerbating Post-Influenza Staphylococcus aureus Super-infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,594,729 | January 21, 2022 | December 31, 2026 | TAM, VINCENT | reporter.nih.gov |
| Regulation of the IgG Fc domain repertoire | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,578,892 | January 15, 2019 | December 31, 2024 | WANG, TAIA | reporter.nih.gov |
| T resident memory in the lung | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,565,922 | April 1, 1998 | October 31, 2023 | HARTY, JOHN T | reporter.nih.gov |
| Triggering germline-encoded broadly neutralizing antibody responses against influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,561,851 | August 19, 2020 | July 31, 2025 | LINGWOOD, DANIEL | reporter.nih.gov |
| DC-subset-tailored vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,560,000 | June 17, 2020 | May 31, 2026 | IGYARTO, BOTOND Z | reporter.nih.gov |
| Immune mechanisms of influenzaâÂÂinduced exacerbation of atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,558,220 | August 15, 2020 | July 31, 2025 | GOPAL, RADHA | reporter.nih.gov |
| Impact of intra-host population structure on influenza virus antigenic evolution | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,543,925 | December 9, 2021 | November 30, 2026 | LOWEN, ANICE C | reporter.nih.gov |
| Investigation of host glycan requirements for the transmission of influenza viruses at the human-animal interface | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,541,846 | July 26, 2024 | June 30, 2029 | MANICASSAMY, BALAJI | reporter.nih.gov |
| Transcriptomic Signatures of Influenza Vaccine Responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,540,548 | January 17, 2018 | December 31, 2024 | POLAND, GREGORY A. | reporter.nih.gov |
| Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,540,227 | September 26, 2023 | August 31, 2026 | NICOLAS, FLORENCE | reporter.nih.gov |
| Novel role for protein kinase D in airway inflammation and antiviral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,540,000 | March 13, 2020 | February 28, 2026 | GEORAS, STEVE N | reporter.nih.gov |
| Understanding evasion of cell intrinsic innate immunity in viral populations with high rates of replicative failure | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,535,710 | August 1, 2022 | May 31, 2027 | RUSSELL, ALISTAIR B | reporter.nih.gov |
| Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,531,885 | February 11, 2021 | November 30, 2023 | PAMULA, VAMSEE K. | reporter.nih.gov |
| A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,525,325 | June 13, 2024 | April 30, 2029 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| The influence of evolutionary landscapes on protective antibody development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,518,710 | January 24, 2019 | December 31, 2024 | WHITEHEAD, TIMOTHY ANDREW | reporter.nih.gov |
| Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,517,506 | September 16, 2019 | August 31, 2025 | KOBIE, JAMES J | reporter.nih.gov |
| Dual oxidase and lactoperoxidase in influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,510,000 | February 19, 2020 | January 31, 2025 | RADA, BALAZS | reporter.nih.gov |
| Predictive Modeling of Estradiol Effects and Sex Differences on Immunopathology during Influenza Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,502,325 | June 18, 2024 | May 31, 2029 | SHOEMAKER, JASON EDWARD | reporter.nih.gov |
| Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,495,366 | January 16, 2018 | December 31, 2023 | SZILAGYI, PETER G | reporter.nih.gov |
| Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,492,136 | June 7, 2019 | August 31, 2023 | DE FIGUEIREDO, PAUL | reporter.nih.gov |
| Impact of Heightened UPR Activation on Inflammasome Responses to Influenza and Secondary Streptococcus pneumoniae Infection in Aged Lung | NIH | National Institute on Aging | 2021 to 2022 | $1,491,600 | May 1, 2018 | April 30, 2024 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| Metal-binding Isosteres for Influenza Endonuclease Inhibitors and Beyond | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,482,645 | April 1, 2020 | March 31, 2026 | COHEN, SETH M | reporter.nih.gov |
| Development of broadly-protective vaccines for influenza B viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,475,893 | July 1, 2023 | June 30, 2027 | KAWAOKA, YOSHIHIRO | reporter.nih.gov |
| Structures and Dynamics of Proton and Cation-Dependent Channels and Transporters | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,474,187 | September 30, 2009 | June 30, 2025 | HONG, MEI | reporter.nih.gov |
| Disease Mechanisms of Prenatal and Pediatric Acquired Hydrocephalus | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,458,488 | April 1, 2020 | March 31, 2026 | CONOVER, JOANNE C | reporter.nih.gov |
| Effects of Vaccination on Acute and Post-Acute Respiratory Viral Infection Outcomes in Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,442,898 | June 13, 2025 | May 31, 2030 | WERBEL, WILLIAM | reporter.nih.gov |
| Motivational Interviewing Training to Promote COVID-19 and Influenza Vaccination (MI-VAX): What Providers Need and Patients Want | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,432,670 | June 27, 2024 | January 31, 2029 | FISHER, KIMBERLY | reporter.nih.gov |
| Lung-on-a-Chip Disease Models for Efficacy Testing | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,413,750 | September 1, 2017 | October 31, 2022 | INGBER, DONALD E | reporter.nih.gov |
| Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,412,604 | March 15, 2021 | February 28, 2027 | ZHANG, LIANGHUI | reporter.nih.gov |
| Sphingolipid signaling in the endothelium during viral host defense | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,405,202 | January 1, 2024 | December 31, 2027 | HLA, TIMOTHY TUN | reporter.nih.gov |
| Negative regulation of innate immunity in influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,396,060 | November 13, 2023 | October 31, 2028 | LI, JIAN-DONG | reporter.nih.gov |
| Overcome immunodominance to support the development of universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,395,922 | August 28, 2024 | June 30, 2029 | LUO, WEI | reporter.nih.gov |
| Longitudinal dynamics of protection after influenza infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,395,852 | July 1, 2019 | June 30, 2025 | COBEY, SARAH | reporter.nih.gov |
| Germline targeting influenza immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,394,075 | August 10, 2017 | July 31, 2024 | NEMAZEE, DAVID | reporter.nih.gov |
| Adenoviral Vector-based Pandemic Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,393,690 | July 1, 2005 | April 30, 2028 | MITTAL, SURESH K | reporter.nih.gov |
| Real-time predictive modeling for public health departments to control infectious diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,389,825 | July 1, 2023 | July 31, 2027 | LO, NATHAN | reporter.nih.gov |
| Shifting immunodominance of humoral immunity against influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,354,521 | August 22, 2023 | July 31, 2028 | GUTHMILLER, JENNA | reporter.nih.gov |
| High resolution profiling and computational modeling of influenza virus-immune dynamics during natural infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,352,292 | February 1, 2025 | January 31, 2030 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| Multiscale modeling of influenza vaccination strategies for optimal T cell immunity | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,349,033 | September 1, 2018 | May 31, 2024 | KOHLMEIER, JACOB E | reporter.nih.gov |
| The role of Bik in the replication and severity of influenza A virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,345,904 | January 1, 2021 | December 31, 2026 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| Dime la VerDAD (Verify, Debunk, and Disseminate) | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $1,339,601 | July 10, 2023 | September 15, 2024 | DEL RIOS, MARINA | reporter.nih.gov |
| A universal intranasal nanoengineered therapy against airborne RNA viruses | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,328,784 | July 3, 2024 | April 30, 2028 | MAHAJAN, VINAY SUBHASH | reporter.nih.gov |
| Synthetic multi-component influenza vaccines to elicit broad immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,325,514 | December 19, 2023 | October 31, 2028 | BOONS, GEERT-JAN | reporter.nih.gov |
| Immunotherapy for acute lung injury secondary to influenza | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,310,316 | April 1, 2020 | March 31, 2025 | KNIGHT III, PAUL R | reporter.nih.gov |
| B and Tfh cell dynamics underlying durable antibody responses to flu vaccine in children | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,297,795 | April 1, 2024 | February 28, 2029 | SINGH, HARINDER | reporter.nih.gov |
| Structure-guided neutralizing antibodies developed using EpiVolve technology | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,291,874 | May 5, 2023 | May 31, 2026 | LI, XIAOFENG | reporter.nih.gov |
| Advancing our knowledge of viral membrane fusion and of IDP-membrane interactions by ESR | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,283,934 | February 1, 2023 | January 31, 2028 | FREED, JACK H | reporter.nih.gov |
| A host-dependent mechanism controlling influenza virus infection by suppressing viral RNA synthesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,271,250 | January 10, 2019 | December 31, 2023 | MARAZZI, IVAN | reporter.nih.gov |
| Small viral RNAs as determinants of influenza A virus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,271,250 | February 4, 2020 | January 31, 2026 | TENOEVER, BENJAMIN R. | reporter.nih.gov |
| Towards a predictive understanding of influenza immunity through experimental data integration, iterative model development, and rigorous assessment of model quality | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,246,617 | December 19, 2024 | November 30, 2029 | PETERS, BJOERN | reporter.nih.gov |
| Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,244,512 | June 18, 2018 | May 31, 2025 | RYTER, KENDAL | reporter.nih.gov |
| Impact of Senolytics on Aged Vaccine Responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,244,166 | November 1, 2022 | October 31, 2027 | BARTLEY, JENNA | reporter.nih.gov |
| Impact of versican deficiency on the innate immune response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,232,686 | December 12, 2017 | November 30, 2023 | FREVERT, CHARLES WAYNE | reporter.nih.gov |
| Immune signatures of vaccine responses in children with sickle cell disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,228,468 | December 1, 2023 | October 31, 2028 | YILDIRIM, INCI BURCIN | reporter.nih.gov |
| Computational Models of Adaptive Immunity to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,225,986 | January 23, 2025 | December 31, 2029 | COBEY, SARAH | reporter.nih.gov |
| Effects of wildfire smoke on respiratory antiviral defense responses | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,217,903 | August 10, 2024 | May 31, 2029 | REBULI, MEGHAN ELIZABETH | reporter.nih.gov |
| Host dependence of influenza A virus spatio-temporal dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,214,178 | December 5, 2016 | August 31, 2029 | LOWEN, ANICE C | reporter.nih.gov |
| Defining the four major routes of MHC class II antigen processing and presentation with influenza antigens | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,213,296 | June 1, 2024 | April 30, 2029 | EISENLOHR, LAURENCE CRANE | reporter.nih.gov |
| Identifying critical determinants of vaccine-induced cellular and humoral immunity from birth through childhood in HIV-exposed and unexposed children | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,202,470 | November 20, 2023 | October 31, 2027 | SLYKER, JENNIFER ANN | reporter.nih.gov |
| HIV-1 Env gp160 maturation in the Golgi apparatus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,199,250 | May 10, 2023 | April 30, 2028 | ZHENG, YONG-HUI | reporter.nih.gov |
| Loss of cellular identity after influenza virus infection and effects on pulmonary function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,197,512 | July 1, 2018 | June 30, 2024 | HEATON, NICHOLAS S | reporter.nih.gov |
| Unravelling highly pathogenic influenza virus emergence | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,196,018 | August 1, 2023 | July 31, 2028 | RICHARD, MATHILDE | reporter.nih.gov |
| Machine Learning to Modulate Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,195,056 | May 19, 2025 | April 30, 2030 | MEILER, JENS | reporter.nih.gov |
| Extrafollicular B cell response regulation during influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,193,272 | June 10, 2024 | May 31, 2029 | BAUMGARTH, NICOLE | reporter.nih.gov |
| How Distinct Age-Associated B Cell Subsets Can Protect the Aged from Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,172,336 | August 19, 2024 | July 31, 2029 | SWAIN, SUSAN L | reporter.nih.gov |
| Influenza Modeling of Correlates of Protection for Optimal Immune Dynamics and Evolution. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,171,832 | December 24, 2024 | November 30, 2029 | MEDINA SILVA, RAFAEL A. | reporter.nih.gov |
| Floss: a novel method for oral mucosal vaccination | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,169,988 | August 1, 2024 | April 30, 2029 | GILL, HARVINDER SINGH | reporter.nih.gov |
| Persistent Post-Viral State of Bacterial Pneumonia Susceptibility and Severity in Down Syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,166,250 | June 1, 2019 | May 31, 2024 | YEAGER, MICHAEL E. | reporter.nih.gov |
| A Microphysiological Mimicry of Human Lung-Bone Marrow Organ-Organ Crosstalk On-a-Chip | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,161,578 | April 1, 2021 | June 30, 2025 | HAJIPOURAN BENAM, KAMBEZ | reporter.nih.gov |
| Development of a Universal Immunotherapeutic for Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,155,553 | March 14, 2019 | March 31, 2023 | HOLTSBERG, FREDERICK WAYNE | reporter.nih.gov |
| Genetic and biophysical mechanisms that control influenza virus cellular multiplicity of infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,155,422 | February 16, 2023 | January 31, 2028 | VAHEY, MICHAEL D | reporter.nih.gov |
| Pathogenic role of IL-17 response in Streptococcus pneumoniae nasopharyngeal pathogenesis during an influenza virus co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,152,158 | December 3, 2019 | November 30, 2025 | KHAN, NADEEM | reporter.nih.gov |
| Mechanism for anti-interferon functions of influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,140,159 | June 20, 2019 | May 31, 2025 | SHI, YUAN | reporter.nih.gov |
| PRC2 independent role of Ezh2 in regulation of basal cell dynamics post-influenza virus infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,126,282 | September 1, 2024 | May 31, 2029 | YAO, CHANGFU | reporter.nih.gov |
| Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,123,469 | August 15, 2017 | July 31, 2024 | DEGROOT, ANNE SEARLS | reporter.nih.gov |
| Influenza regulation of epithelial pneumococcal host defense. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,113,750 | September 10, 2020 | August 31, 2025 | HARROD, KEVIN S | reporter.nih.gov |
| Control of Influenza Infection by Lipid Mediators and Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,099,522 | January 10, 2018 | December 31, 2024 | HAHN, YOUNG S. | reporter.nih.gov |
| Armed nanobodies as anti-infectives and anti-tumor agents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,085,800 | July 19, 2024 | May 31, 2029 | WU, HAO | reporter.nih.gov |
| Multiscale Modeling of Influenza Neutralizing Antibody and Fc Effector Biology | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,082,429 | December 19, 2024 | November 30, 2029 | CHAN, CLIBURN C | reporter.nih.gov |
| HLA-DO / H2-O: modulation of MHC-II peptide diversity and Treg population control | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,082,364 | December 12, 2017 | November 30, 2023 | STERN, LAWRENCE J. | reporter.nih.gov |
| Endothelial cell tropism in the pathogenesis and host response against influenza viruses - Resubmission 01 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,080,542 | December 8, 2017 | November 30, 2023 | MANICASSAMY, BALAJI | reporter.nih.gov |
| Characterization of a distinct NKT subset and its role in influenza responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,075,834 | May 1, 2018 | April 30, 2024 | ALBEROLA-ILA, JOSE | reporter.nih.gov |
| Inducible HMGB1 antagonist for viral-induced acute lung injury. | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,068,694 | August 16, 2023 | July 31, 2025 | BLANCO, JORGE C | reporter.nih.gov |
| Biomimetic nanoparticles to enhance the breadth of influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,062,524 | August 7, 2020 | July 31, 2025 | WU, MEI X | reporter.nih.gov |
| Innate-like BCR activity as a template for universal vaccination against influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,058,052 | June 1, 2018 | May 31, 2023 | LINGWOOD, DANIEL | reporter.nih.gov |
| The role of Nrf2 in T cell function and influenza | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,053,331 | July 6, 2024 | April 30, 2029 | ROCKWELL, CHERYL ELIZABETH | reporter.nih.gov |
| Addressing unanticipated events for Intranasal Influenza H5 Vaccine Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,052,554 | August 8, 2022 | July 31, 2024 | ORTIZ, JUSTIN R. | reporter.nih.gov |
| IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,048,815 | August 1, 2015 | June 30, 2026 | BILSEL, PAMUK | reporter.nih.gov |
| Influenza D Virus Entry and Tissue Tropism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,033,696 | September 21, 2018 | August 31, 2025 | LI, FENG | reporter.nih.gov |
| The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,032,987 | May 13, 2021 | April 30, 2027 | RAJSBAUM, RICARDO | reporter.nih.gov |
| Age related loss of immune resilience during response to severe respiratory viral infections | NIH | National Institute on Aging | 2024 to 2025 | $1,028,435 | July 1, 2024 | April 30, 2029 | SEGAL, LEOPOLDO NICOLAS | reporter.nih.gov |
| Oxidative Burst in Influenza and MRSA Co-infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,022,922 | May 22, 2013 | December 31, 2024 | SUN, KEER | reporter.nih.gov |
| Dissecting the viral and host constraints that govern influenza virus antigenic evolution | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,013,305 | December 1, 2023 | October 31, 2028 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,013,003 | August 1, 2025 | July 31, 2028 | HUTCHINS, JEFF T | reporter.nih.gov |
| Automated Surveillance of Overlapping Outbreaks and New Outbreak Diseases | NIH | National Library of Medicine | 2021 to 2023 | $1,008,755 | August 3, 2021 | July 31, 2025 | COOPER, GREGORY F. | reporter.nih.gov |
| AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,004,473 | September 10, 2025 | August 31, 2028 | WEINBERGER, ARIEL | reporter.nih.gov |
| Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | July 3, 2023 | December 31, 2026 | DAVENPORT, GREGORY | reporter.nih.gov |
| Improved Influenza Vaccine Efficacy Through Infection Mimicry | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $999,900 | April 15, 2019 | January 31, 2022 | KOSUDA, KATHRYN | reporter.nih.gov |
| Flu Dynamics COVID-19 Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $983,380 | July 28, 2020 | December 31, 2023 | GORDON, AUBREE L | reporter.nih.gov |
| Causal Inference in Infectious Disease Prevention Studies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $982,276 | December 1, 2009 | May 31, 2026 | HUDGENS, MICHAEL G | reporter.nih.gov |
| Innate Control of Adaptive Immunity to SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $968,772 | June 1, 2021 | May 31, 2026 | GOLDMAN-ISRAELOW, BENJAMIN | reporter.nih.gov |
| Balancing protective immunity and chronic sequelae by resident CD8 T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $966,944 | August 20, 2020 | December 31, 2021 | SUN, JIE | reporter.nih.gov |
| Protection of at-risk low birth weight infants against influenza via maternal antibody | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $942,300 | June 1, 2021 | May 31, 2026 | KACHIKIS, ALISA | reporter.nih.gov |
| INFLUENZA-SPECIFIC IMMUNITY AND RESPONSES TO INACTIVATED INFLUENZA VACCINE IN INFANTS: EFFECT OF MATERNAL VACCINATION DURING PREGNANCY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $932,996 | June 18, 2020 | May 31, 2025 | WEINBERG, ADRIANA | reporter.nih.gov |
| Regulation of IL10 production in CD8+ T cells during Flu infection by tyrosine kinase Itk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $921,550 | June 18, 2018 | May 31, 2024 | AUGUST, AVERY | reporter.nih.gov |
| B-1 cells, IgM and Protective Humoral Immunity to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $913,429 | September 23, 2019 | August 31, 2025 | BAUMGARTH, NICOLE | reporter.nih.gov |
| Mechanisms of age-specific differences in the Type I IFN response to respiratory viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $901,284 | September 8, 2020 | August 31, 2024 | CAREY, ALISON J | reporter.nih.gov |
| Predictive Modeling of Influenza-Pneumococcal Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $885,870 | July 1, 2018 | June 30, 2024 | SMITH, AMBER M | reporter.nih.gov |
| Infant Protection from Influenza through Maternal Influenza Immunization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $874,965 | June 1, 2021 | May 31, 2027 | RICK, ANNE-MARIE | reporter.nih.gov |
| Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $864,948 | July 3, 2023 | December 31, 2026 | DAVENPORT, GREGORY | reporter.nih.gov |
| The basis of Influenza A virus strain-dependent reassortment potential | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $858,639 | February 14, 2024 | January 31, 2029 | DIAZ, SAMUEL L | reporter.nih.gov |
| Defining the Role of ANKEF1 in Ciliary Function and Host Defense Against Influenza Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $856,791 | September 12, 2025 | August 31, 2026 | MIORIN, LISA | reporter.nih.gov |
| Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $847,917 | August 13, 2021 | July 31, 2023 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Harnessing ZBP1-triggered cell death to enhance influenza vaccine responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $833,534 | August 7, 2023 | July 31, 2024 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Explore a key nucleotide synthesis enzyme to develop a broad-spectrum antiviral therapy. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $831,235 | August 21, 2025 | July 31, 2030 | FENG, PINGHUI | reporter.nih.gov |
| Biology and infection of bats with novel bat influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $824,854 | January 10, 2018 | December 31, 2024 | MA, WENJUN | reporter.nih.gov |
| Novel adjuvant to boost humoral and cellular immune responses against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $820,609 | May 15, 2018 | April 30, 2025 | CHEN, XINYUAN | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $813,514 | May 8, 2020 | April 30, 2023 | CRAIGO, JODI K | reporter.nih.gov |
| Assessing functional immunity to influenza infection by quantifying BCR binding avidities | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $811,009 | November 13, 2024 | October 31, 2029 | GEORGE, STEVEN CARL | reporter.nih.gov |
| Impact of prior influenza exposures on antibody repertoires to new viral strains | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $807,244 | August 15, 2014 | July 31, 2024 | HENSLEY, SCOTT ERIC | reporter.nih.gov |
| Mechanisms of regulatory T-cell mediated endothelial repair following viral pneumonia in aged hosts | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $805,882 | September 20, 2021 | August 31, 2026 | MORALES-NEBREDA, LUISA | reporter.nih.gov |
| Detrimental Effects of B-Cell-Th17 Axis in Antiviral Immunity in Smokers. | NIH | National Heart, Lung, and Blood Institute | 2025 | $799,998 | September 1, 2025 | May 31, 2030 | KHERADMAND, FARRAH | reporter.nih.gov |
| Role of Microbiome in Neonatal Lung Maturation and Immune Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $799,909 | March 19, 2018 | February 29, 2024 | MILLER, LISA A | reporter.nih.gov |
| Protecting Patients with Glomerular Disease from Vaccine-Preventable Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $795,246 | February 15, 2022 | January 31, 2027 | GLENN, DOREY | reporter.nih.gov |
| The interplay of maternal antibody and newborn vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $793,102 | April 17, 2025 | March 31, 2030 | ALEXANDER-MILLER, MARTHA ANN | reporter.nih.gov |
| Molecular Mechanism of Action of the Influenza PA-X Host Shutoff Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $788,424 | May 25, 2018 | April 30, 2024 | GAGLIA, MARTA MARIA | reporter.nih.gov |
| iPSC-derived macrophages as a model to study the genetic basis of inter-individual variation in immune responses to pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $785,511 | January 24, 2025 | December 31, 2029 | BARREIRO, LUIS BRUNO | reporter.nih.gov |
| The Impact of Aging and HIV Infection on Immunologic and Transcriptomic Signatures of Influenza Vaccine Response | NIH | National Institute on Aging | 2021 | $779,116 | August 15, 2017 | April 30, 2023 | SHAW, ALBERT C | reporter.nih.gov |
| Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $777,500 | August 15, 2018 | June 30, 2024 | ANTONIAK, SILVIO | reporter.nih.gov |
| Mechanisms of Protection of Universal Therapeutic Antibodies to Influenza A | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $773,720 | January 1, 2019 | December 31, 2023 | PAUST, SILKE | reporter.nih.gov |
| Unfolded protein response in Influenza virus infection and inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,859 | January 15, 2019 | December 31, 2023 | ANATHY, VIKAS | reporter.nih.gov |
| Structure and functional dynamics of virus-host protein interactions | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $772,397 | September 20, 2018 | August 31, 2024 | CHO, JAE HYUN | reporter.nih.gov |
| The effects of influenza virus genomic heterogeneity on replication dynamics and the host response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $770,146 | September 21, 2018 | August 31, 2024 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| Elucidating Olfactory Epithelial Anti-Viral Responses in Persistent Post-Viral Olfactory Dysfunction | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2025 | $767,492 | February 1, 2022 | January 31, 2027 | YAN, CAROL H | reporter.nih.gov |
| Early Events in Protein Folding | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $759,805 | June 1, 1996 | July 31, 2024 | DYER, RICHARD BRIAN | reporter.nih.gov |
| Molecular Basis for the TREX-2 mRNA Nuclear Export Pathway | NIH | National Institute of General Medical Sciences | 2025 | $758,594 | September 1, 2025 | August 31, 2027 | FONTOURA, BEATRIZ MA | reporter.nih.gov |
| Pathogenic mechanisms of chronic lung sequelae following respiratory viral infection | NIH | National Heart, Lung, and Blood Institute | 2025 | $754,729 | August 10, 2025 | May 31, 2029 | ZHANG, LIANGHUI | reporter.nih.gov |
| The role of Bik in the replication and severity of influenza A virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $754,629 | January 1, 2021 | August 8, 2022 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| Identifying mechanisms by which metformin regulates T cell responses in obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $753,296 | December 20, 2024 | November 30, 2029 | MACIVER, NANCIE | reporter.nih.gov |
| Exploring the role of T cells in protection from respiratory virus transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $744,977 | February 1, 2025 | January 31, 2030 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Strain Dependent Structure and Function of the Influenza NS1 Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $742,500 | November 16, 2017 | October 31, 2024 | PETIT, CHAD | reporter.nih.gov |
| Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $740,465 | May 22, 2017 | April 30, 2023 | TRENT, MICHAEL STEPHEN | reporter.nih.gov |
| Oseltamivir Use and Risk of Serious Neuropsychiatric Adverse Events in Children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $740,087 | March 1, 2022 | February 28, 2026 | ANTOON, JAMES W | reporter.nih.gov |
| Combustion Generated Particulate Pollution Affects Infant Respiratory Health | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $735,130 | September 1, 2006 | August 31, 2024 | CORMIER, STEPHANIA A | reporter.nih.gov |
| Mechanistic bases of strain-specific virus-host interactions | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $729,993 | February 1, 2024 | January 31, 2029 | CHO, JAE HYUN | reporter.nih.gov |
| Monocyte-derived galectin-1 promotes tissue-resident memory T cell response | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $722,958 | November 22, 2024 | October 31, 2029 | KIM, MINSOO | reporter.nih.gov |
| Mentoring in transmission of influenza and strategies for prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $714,408 | February 3, 2020 | October 31, 2025 | GRIJALVA, CARLOS G | reporter.nih.gov |
| REINVIGORATE: Repeated Enhanced INfluenza Vaccines In Geriatrics of a Randomised trial for Antibody and T cell Effects | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $711,626 | April 11, 2024 | March 31, 2029 | DOAK, SOPHIE ALESSANDRA VALKENBURG | reporter.nih.gov |
| Glycan-Mediated Impacts on the Mucus Barrier Towards Respiratory Viruses | NIH | National Heart, Lung, and Blood Institute | 2025 | $711,144 | September 1, 2025 | June 30, 2029 | SCULL, MARGARET ADELE | reporter.nih.gov |
| Effects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $704,782 | April 1, 2017 | March 31, 2024 | BOYD, SCOTT DEXTER | reporter.nih.gov |
| Immunity in the Nose to inFLUENza: Correlates of Efficacy (INFLUENCE) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $701,638 | May 4, 2023 | April 30, 2025 | THWAITES, RYAN | reporter.nih.gov |
| Community - based behavioral intervention to increase COVID - 19 and influenza vaccination for African American/ Black and Latino persons: An optimization randomized controlled trial | NIH | National Institute on Minority Health and Health Disparities | 2024 | $688,573 | September 22, 2024 | April 1, 2025 | GWADZ, MARYA | reporter.nih.gov |
| Nanovaccine-Mediated Immune Protection Against Influenza Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $680,912 | June 1, 2017 | May 31, 2023 | LEGGE, KEVIN L | reporter.nih.gov |
| Spatial and Temporal Adjuvant Delivery for Skin mRNA Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $676,666 | September 3, 2025 | August 31, 2030 | WU, MEI X | reporter.nih.gov |
| Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $675,832 | February 1, 2017 | January 31, 2023 | ZAND, MARTIN S | reporter.nih.gov |
| Role of respiratory viral infections and inflammation in promoting metastatic outgrowth in the lung | NIH | National Cancer Institute | 2025 | $672,011 | March 1, 2025 | February 28, 2030 | DEGREGORI, JAMES V | reporter.nih.gov |
| Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $668,569 | August 23, 2024 | June 30, 2029 | ZABALETA, NEREA | reporter.nih.gov |
| Hospital adaptation and resiliency for infected and uninfected patients during respiratory viral surge events: from seasonal influenza to COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $664,475 | December 15, 2021 | November 30, 2026 | ANESI, GEORGE L | reporter.nih.gov |
| Task A04: Mouse Models for Evaluation of Therapeutics against Human Seasonal Influenza and Avian Influenza Strains with Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $663,068 | September 24, 2024 | September 23, 2025 | COOK, MIKAYLA | reporter.nih.gov |
| Mechanisms of influenza transmission bottlenecks: impact on viral evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $659,143 | January 1, 2017 | December 31, 2023 | FRIEDRICH, THOMAS C. | reporter.nih.gov |
| Role of preexisting immunity on airborne transmission of influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $644,203 | February 22, 2022 | January 31, 2023 | LAKDAWALA, SEEMA S. | reporter.nih.gov |
| Mechanisms of CD8 TRM-mediated protection against respiratory virus transmission | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $640,735 | July 26, 2024 | June 30, 2025 | KOHLMEIER, JACOB E | reporter.nih.gov |
| CD38, T cells and post viral lung sequelae during aging | NIH | National Institute on Aging | 2025 | $639,740 | December 15, 2024 | November 30, 2029 | SUN, JIE | reporter.nih.gov |
| Implementation research to improve the uptake of influenza vaccination in CKD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $627,765 | August 4, 2021 | March 10, 2025 | ISHIGAMI, JUNICHI | reporter.nih.gov |
| New Nasal Spray Influenza Vaccine for Children (Research Supplement for Post Baccalaureate Diversity Candidate) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $625,772 | March 10, 2023 | February 28, 2026 | ZENG, MINGTAO | reporter.nih.gov |
| Gene regulatory network of memory B cell and long-lived plasma cell differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $625,348 | July 3, 2025 | June 30, 2030 | ROY, KOUSHIK | reporter.nih.gov |
| Developing mRNAdesigner tool package for optimization of mRNA sequence | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $624,000 | September 30, 2024 | June 30, 2028 | ZHOU, XIAOBO | reporter.nih.gov |
| Predictors of Influenza-Associated Absenteeism and Impact of Vaccination in a Cohort of Guatemalan Agricultural Workers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $619,202 | September 11, 2019 | August 31, 2024 | OLSON, DANIEL | reporter.nih.gov |
| Targeted genetic engineering of B cells to induce protective antibody responses to pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $618,943 | July 5, 2022 | June 30, 2027 | ADAIR, JENNIFER EILEEN | reporter.nih.gov |
| Eosinophils as Effectors of Antibacterial Immunity in the Lungs | NIH | National Heart, Lung, and Blood Institute | 2024 | $615,455 | September 1, 2024 | June 30, 2028 | SAMARASINGHE, AMALI | reporter.nih.gov |
| Eosinophils as Effectors of Antibacterial Immunity in the Lungs | NIH | National Heart, Lung, and Blood Institute | 2025 | $613,501 | September 1, 2024 | June 30, 2028 | SAMARASINGHE, AMALI E | reporter.nih.gov |
| Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $610,868 | August 27, 2021 | July 31, 2025 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| The Role of Ariadne RBR E3 ubiquitin protein ligase 2 (ARIH2) in influenza A virus replication and pathogenesis in the airway epithelial cells | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $605,778 | July 7, 2025 | June 30, 2030 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| Encephalitic viral infection and susceptibility to dopaminergic neurotoxins | NIH | National Institute of Environmental Health Sciences | 2021 | $603,534 | September 20, 2019 | August 31, 2024 | TJALKENS, RONALD | reporter.nih.gov |
| Arsenic and immune response to influenza vaccination in pregnant women and newborns | NIH | National Institute of Environmental Health Sciences | 2021 | $600,834 | March 1, 2017 | November 30, 2023 | HEANEY, CHRISTOPHER D | reporter.nih.gov |
| Novel Hybrid Computational Models to Disentangle Complex Immune Responses | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $600,000 | September 26, 2023 | August 31, 2027 | HERNANDEZ VARGAS, ESTEBAN ABELARDO | reporter.nih.gov |
| TFH-TARGETING GENETIC ADJUVANTS TO PROMOTE DURABLE ANTI-INFLUENZA STEM ANTIBODIES IN OLDER ADULTS. | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,980 | September 30, 2023 | September 29, 2025 | SINGLETON, KENTNER | reporter.nih.gov |
| DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,925 | September 30, 2023 | September 29, 2025 | ONHO, SAM | reporter.nih.gov |
| MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,806 | September 30, 2023 | September 29, 2025 | SINGLETON, KENTNER | reporter.nih.gov |
| Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $599,788 | August 11, 2022 | July 31, 2025 | GOMPERTS, EDWARD | reporter.nih.gov |
| DEVELOPMENT OF TOLL-LIKE RECEPTOR AGONISTS TO STRENGTHEN SUBLINGUAL VACCINES. | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $599,582 | January 10, 2022 | January 9, 2024 | FANGER, NEIL | reporter.nih.gov |
| A more durable and universal adjuvanted influenza vaccine through synthetic biology | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $599,526 | June 1, 2025 | May 31, 2027 | KEMPINSKI, CHASE | reporter.nih.gov |
| APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS. | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $597,598 | January 10, 2022 | January 9, 2024 | ROTHSTEIN, SAM | reporter.nih.gov |
| MRNA VACCINE DEVELOPMENT | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $594,566 | September 1, 2024 | August 31, 2026 | ANDRIANOVA, KATERINA | reporter.nih.gov |
| A Novel Broad-spectrum Antiviral Agent | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $590,654 | January 1, 2021 | December 31, 2022 | MURAD, JOANA M | reporter.nih.gov |
| Mechanisms by which NS1 and NEP govern the influenza lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $587,885 | September 18, 2025 | August 31, 2030 | PETIT, CHAD | reporter.nih.gov |
| The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $582,371 | May 13, 2021 | April 30, 2023 | RAJSBAUM, RICARDO | reporter.nih.gov |
| Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $564,041 | March 15, 2021 | June 30, 2022 | ZHANG, LIANGHUI | reporter.nih.gov |
| Synthetic multi-component influenza vaccines to elicit broad immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $562,640 | August 13, 2021 | July 31, 2023 | BOONS, GEERT-JAN | reporter.nih.gov |
| Obesity dysregulates immune and metabolic status in asthma and alters infection susceptibility. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $560,844 | December 14, 2018 | November 30, 2023 | HENRICKSON, SARAH E | reporter.nih.gov |
| Biology of Influenza Virus Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $559,056 | June 8, 2019 | May 31, 2025 | ORTIGOZA, MILA BRUM | reporter.nih.gov |
| Use of probiotics to modulate antimicrobial peptide signaling in the neonatal innate immune response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $554,786 | September 17, 2025 | August 31, 2027 | CAREY, ALISON J | reporter.nih.gov |
| B-1 cells, IgM and Protective Humoral Immunity to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $553,449 | September 23, 2019 | August 31, 2022 | BAUMGARTH, NICOLE | reporter.nih.gov |
| Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $544,376 | February 10, 2017 | January 31, 2023 | VOGEL, STEFANIE N. | reporter.nih.gov |
| Macrophage differentiation and disease outcome in influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $542,926 | December 5, 2016 | November 30, 2023 | VOGEL, STEFANIE N. | reporter.nih.gov |
| Effect of Neonatal Hyperoxia on Alveolar Development and Infection | NIH | National Heart, Lung, and Blood Institute | 2021 | $536,581 | December 10, 2008 | August 31, 2023 | O'REILLY, MICHAEL A | reporter.nih.gov |
| Functional Implications of Tfh Cell Heterogeneity after Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $536,245 | August 20, 2021 | July 31, 2022 | BALLESTEROS-TATO, ANDRE | reporter.nih.gov |
| Investigating Transplacental Immune Pathways Contributing to Fetal Brain Pathology in Maternal Influenza | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $535,039 | September 10, 2025 | May 31, 2030 | ANTONSON, ADRIENNE M | reporter.nih.gov |
| Consequences of Direct Viral-Bacterial Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $531,058 | July 20, 2021 | June 30, 2023 | ROSCH, JASON W. | reporter.nih.gov |
| IDENTIFICATION AND CHARACTERIZATION OF RNA STRUCTURES IN THE GENOME OF INFLUENZA VIRUS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $521,901 | July 13, 2018 | June 30, 2023 | BOON, ADRIANUS CM | reporter.nih.gov |
| Single-cell dissection of CD4 T cell changes in patients with immune-related adverse events following PD-1 inhibition | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $519,072 | February 1, 2023 | December 31, 2027 | APOSTOLIDIS, SOKRATIS | reporter.nih.gov |
| Impact of Early-in-life Disruption of Lung Development on Adult Lung Progenitor Function | NIH | National Heart, Lung, and Blood Institute | 2021 | $516,867 | September 1, 2018 | June 30, 2023 | SUN, XIN | reporter.nih.gov |
| Alveolar macrophage-derived extracellular vesicles inhibit influenza infection in epithelial cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $508,680 | August 15, 2019 | September 9, 2023 | SCHNEIDER, DANIEL J | reporter.nih.gov |
| Characterization of seasonal CoV immunity and operationalization of a novel controlled human infection model for the betacoronavirus OC43 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $502,779 | May 25, 2023 | April 30, 2027 | DEMING, MEAGAN ELISE | reporter.nih.gov |
| Midcareer Investigator Award in Patient-Oriented Research in the Microbiome and Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $500,124 | May 1, 2022 | April 30, 2027 | DICKSON, ROBERT PICKETT | reporter.nih.gov |
| Quantifying the genetic and environmental factors driving avian influenza spillover | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $498,000 | September 1, 2022 | August 31, 2025 | MONCLA, LOUISE HILLIER | reporter.nih.gov |
| Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities: A Pilot Pragmatic Trial | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $495,277 | September 1, 2022 | March 10, 2025 | WILLIAMS, JOSHUA TYLER BONNEMA | reporter.nih.gov |
| Social and policy determinants and impacts on COVID-19 and influenza disparities | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $492,491 | February 10, 2022 | January 31, 2027 | SCHNAKE-MAHL, ALINA | reporter.nih.gov |
| IFN/SOCS1 signaling during post-influenza bacterial infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $489,965 | September 1, 2025 | August 31, 2026 | SUN, KEER | reporter.nih.gov |
| Mitochondrial metabolic regulation of lung epithelium: alveolar generation and regeneration | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $489,888 | September 17, 2019 | August 31, 2024 | HAN, SEUNGHYE | reporter.nih.gov |
| Creating Innovative Vaccine Messaging by Engaging in Patient-Centered Design with Non-Vaccinating Older Adults | NIH | National Institute on Aging | 2021 to 2024 | $488,528 | August 1, 2020 | April 1, 2025 | SCHERER, AARON MICHAEL | reporter.nih.gov |
| Integrative Multi-Scale Systems Analysis of Gene-Expression-Driven Aging Morbidity | NIH | National Institute on Aging | 2024 to 2025 | $485,270 | September 15, 2020 | December 31, 2026 | STOEGER, THOMAS | reporter.nih.gov |
| Real-time predictive modeling for public health departments to control infectious diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $484,500 | August 1, 2022 | June 30, 2023 | LO, NATHAN | reporter.nih.gov |
| Alu dsRNAs as adjuvants for influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $481,990 | April 7, 2022 | March 31, 2025 | AUNE, THOMAS M. | reporter.nih.gov |
| Pulmonary Epithelial Dynamics and Innate Host Defense | NIH | National Heart, Lung, and Blood Institute | 2021 | $480,973 | December 7, 2017 | November 30, 2022 | MCCORMACK, FRANCIS XAVIER | reporter.nih.gov |
| Verification of pigs as an appropriate model for the development of human vaccines targeting the entero-mammary pathway to elicit a robust secretory IgA response in human milk | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $477,406 | September 3, 2025 | August 31, 2027 | POWELL, REBECCA | reporter.nih.gov |
| Developing broad-based treatments for respiratory viruses by targeting host cell TTSPs | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $477,146 | March 20, 2024 | February 28, 2026 | WHITTAKER, GARY R | reporter.nih.gov |
| Nasal RNA response to respiratory viral infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $472,750 | April 1, 2022 | March 31, 2024 | PAN, TAO | reporter.nih.gov |
| Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $472,250 | June 20, 2024 | April 30, 2026 | SCHOTSAERT, MICHAEL | reporter.nih.gov |
| ILC2-Mediated Protection from Acute Lung Infection | NIH | National Heart, Lung, and Blood Institute | 2021 | $469,445 | December 12, 2017 | November 30, 2022 | METZGER, DENNIS W | reporter.nih.gov |
| Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $465,750 | February 22, 2023 | January 31, 2025 | SCHOTSAERT, MICHAEL | reporter.nih.gov |
| Regulation of Follicular T cell Responses in the Lung by Ion Channels | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $465,462 | September 25, 2017 | August 31, 2023 | FESKE, STEFAN | reporter.nih.gov |
| Role of a novel human-virus chimeric protein generated by upstream translation and genetic overprinting | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $464,875 | November 1, 2021 | October 31, 2023 | MARAZZI, IVAN | reporter.nih.gov |
| Epigenetic Histone Landscape Profiles in HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $463,003 | July 21, 2022 | June 30, 2025 | UTZ, PAUL JOSEPH | reporter.nih.gov |
| The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $461,016 | May 13, 2021 | April 30, 2022 | RAJSBAUM, RICARDO | reporter.nih.gov |
| Host response-based screening for unexpected or emerging respiratory viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $460,625 | March 15, 2021 | February 28, 2023 | FOXMAN, ELLEN FLESCHER | reporter.nih.gov |
| Age-Associated B Cells Specialized for Immunity to Pathogens? | NIH | National Institute on Aging | 2021 to 2022 | $460,625 | May 15, 2021 | January 31, 2023 | SWAIN, SUSAN L | reporter.nih.gov |
| Harnessing Age-Associated B cells for a Universal Influenza Vaccine for the Aged | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $460,625 | November 3, 2022 | October 31, 2025 | SWAIN, SUSAN L | reporter.nih.gov |
| Identification of lung resident innate lymphocytes that specifically protect neonates from SARS-CoV-2 infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $460,625 | August 8, 2023 | July 31, 2025 | KANG, JOONSOO | reporter.nih.gov |
| Platelet-MLKL role in S100 Release with Age and Infection | NIH | National Institute on Aging | 2025 | $460,625 | May 15, 2025 | April 30, 2027 | KOUPENOVA, MILKA | reporter.nih.gov |
| A decision tool to inform the optimal use of non-pharmaceutical interventions during the COVID-19 pandemic | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $459,884 | July 25, 2023 | June 30, 2026 | YAESOUBI, REZA | reporter.nih.gov |
| Adjuvanted Intranasal influenza vaccine to generate lung resident-memory T cells | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $454,278 | August 15, 2025 | July 31, 2027 | GANDHAPUDI, SIVA KUMAR | reporter.nih.gov |
| The impact of senescence on immune memory | NIH | National Institute on Aging | 2023 | $453,163 | September 15, 2023 | September 14, 2025 | HAYNES, LAURA | reporter.nih.gov |
| Can Senolytics Improve the Aged Response to Viral Infection | NIH | National Institute on Aging | 2021 to 2022 | $451,000 | September 1, 2021 | May 31, 2024 | HAYNES, LAURA | reporter.nih.gov |
| Programming Offspring Immunity By In Utero Exposure to Maternal Helminth Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $451,000 | August 1, 2025 | July 31, 2027 | REESE, TIFFANY ANNE | reporter.nih.gov |
| mRNA vaccine responses in PLWH | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $450,313 | August 22, 2022 | July 31, 2024 | BLANKSON, JOEL N | reporter.nih.gov |
| Environmental arsenic, immunoregulation, and viral disease risk | NIH | National Institute of Environmental Health Sciences | 2022 to 2023 | $450,288 | March 11, 2022 | August 31, 2024 | COFFMAN, JAMES A | reporter.nih.gov |
| Role of ATII cell senescence in influenza pathogenesis in aging | NIH | National Institute on Aging | 2023 | $448,270 | September 1, 2023 | August 31, 2025 | DAVIS, IAN CHRISTOPHER | reporter.nih.gov |
| Leveraging Pathogen-Host Networks to Identify Virus-specific and Estradiol-regulated Mechanisms during Respiratory Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $447,935 | June 9, 2023 | May 31, 2026 | SHOEMAKER, JASON EDWARD | reporter.nih.gov |
| A revised model for immune imprinting by influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $447,212 | June 1, 2022 | May 31, 2026 | SANT, ANDREA JANINE | reporter.nih.gov |
| Tuft Cells Modulate Macrophage Response Following Lung Viral Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $445,500 | February 1, 2022 | January 31, 2025 | QUE, JIANWEN | reporter.nih.gov |
| Mechanism of membrane inactivation method to prepare enveloped virus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $444,397 | June 23, 2021 | May 31, 2024 | AGUILAR-CARRENO, HECTOR | reporter.nih.gov |
| Dissecting ADP-ribosylation as an innate immune response countering influenza virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $443,476 | September 22, 2021 | August 31, 2024 | MEHLE, ANDREW | reporter.nih.gov |
| Methods for Estimating Disease Burden of Seasonal Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $443,389 | July 6, 2023 | June 30, 2026 | CHANG, HOWARD H | reporter.nih.gov |
| Microglia mediate cognitive dysfunction in elderly survivors of pneumonia | NIH | National Institute on Aging | 2022 | $440,000 | February 1, 2022 | January 31, 2025 | MISHARIN, ALEXANDER | reporter.nih.gov |
| Individual and Neighborhood Vulnerability to the Spanish Flu | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $438,625 | May 1, 2023 | April 30, 2025 | LOGAN, JOHN R | reporter.nih.gov |
| Sequence specific determinants, and impacts, of NS2 interactions with the influenza A virus polymerase | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $438,500 | July 8, 2025 | June 30, 2027 | RUSSELL, ALISTAIR B | reporter.nih.gov |
| Development of a Novel rAAV Vector Without Cross-species Barrier to Transduce Human and Ferret Conducting Airways | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $438,238 | June 15, 2021 | May 31, 2024 | QIU, JIANMING | reporter.nih.gov |
| Targeting IKK-alpha in lymphatics to drive protective tertiary lymphoid organ formation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $434,375 | January 24, 2023 | December 31, 2025 | MAY, MICHAEL J | reporter.nih.gov |
| Tetrahydrothieno[2,3-c]pyridines as Vaccine Co-adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $434,000 | November 25, 2020 | October 31, 2022 | SHUKLA, NIKUNJ | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York, NY | 28 | $174.9 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 1 | $150.3 million | 0 | $0 |
| Duke University | Durham, NC | 16 | $139.4 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 15 | $132.7 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 11 | $82.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 30 | $74.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 19 | $68.9 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 9 | $57 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 15 | $44.3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 6 | $37.6 million | 0 | $0 |
| University of Chicago | Chicago, IL | 14 | $35.4 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 11 | $29.8 million | 0 | $0 |
| University of Washington | Seattle, WA | 10 | $28.2 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 12 | $26.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 13 | $23.9 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 24 | $23.5 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 2 | $23.4 million | 0 | $0 |
| Digital Infuzion, Inc. | Rockville, MD | 2 | $22.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 8 | $22 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 8 | $21 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 12 | $18.1 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 12 | $18 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 12 | $15.6 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 8 | $14.8 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 4 | $14.7 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 2 | $14.4 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 3 | $14.1 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 10 | $13.8 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 11 | $13.6 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 12 | $13.5 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 3 | $13.4 million | 0 | $0 |
| University of Montana | Missoula, MT | 2 | $12.9 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 7 | $12.2 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 6 | $11.5 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 8 | $10.9 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 6 | $10.9 million | 0 | $0 |
| Versatope Therapeutics, Inc. | Lowell, MA | 1 | $10.9 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 7 | $10.7 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 14 | $10.3 million | 0 | $0 |
| Regents of the University of Idaho | Moscow, ID | 2 | $10.3 million | 0 | $0 |
| Yale University | New Haven, CT | 11 | $9.5 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 6 | $9 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 6 | $8.5 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 9 | $8.5 million | 0 | $0 |
| Ohio State University | Columbus, OH | 10 | $8.2 million | 0 | $0 |
| Rockefeller University | New York, NY | 2 | $8.2 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 4 | $8.1 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 5 | $7.9 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 10 | $7.8 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 6 | $7.3 million | 0 | $0 |
| University of Maryland Baltimore County | Baltimore, MD | 1 | $7.1 million | 0 | $0 |
| Washington State University | Pullman, WA | 2 | $7.1 million | 0 | $0 |
| Iowa State University | Ames, IA | 3 | $7 million | 0 | $0 |
| Washington University | Saint Louis, MO | 9 | $6.8 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 2 | $6.7 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 3 | $6.7 million | 0 | $0 |
| TSRL, Inc. | Ann Arbor, MI | 3 | $6.5 million | 0 | $0 |
| University of California-San Diego Scripps Inst of Oceanography | La Jolla, CA | 1 | $6.4 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 5 | $6.3 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 7 | $6.3 million | 0 | $0 |
| Orlance, Inc. | Seattle, WA | 3 | $6.3 million | 0 | $0 |
| University of Rochester | Rochester, NY | 11 | $5.9 million | 0 | $0 |
| Inimmune Corporation | Missoula, MT | 1 | $5.9 million | 0 | $0 |
| International Aids Vaccine Initiative | New York, NY | 1 | $5.6 million | 0 | $0 |
| Greffex, Inc. | Aurora, CO | 1 | $5.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 7 | $5 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 4 | $4.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 3 | $4.9 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 1 | $4.8 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 4 | $4.7 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 4 | $4.7 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 3 | $4.2 million | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 3 | $4.2 million | 0 | $0 |
| Vaxess Technologies, Inc. | Cambridge, MA | 2 | $3.8 million | 0 | $0 |
| New York Blood Center | New York, NY | 1 | $3.7 million | 0 | $0 |
| Flugen, Inc. | Madison, WI | 2 | $3.7 million | 0 | $0 |
| University of California at Davis | Davis, CA | 6 | $3.6 million | 0 | $0 |
| Enepret, Inc. | Lexington, KY | 2 | $3.6 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 4 | $3.5 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 2 | $3.5 million | 0 | $0 |
| Chicago Biosolutions, Inc. | Chicago, IL | 1 | $3.3 million | 0 | $0 |
| Rensselaer Polytechnic Institute | Troy, NY | 1 | $3.3 million | 0 | $0 |
| Brown University | Providence, RI | 2 | $3.2 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 3 | $3.2 million | 0 | $0 |
| Tiba Biotech, LLC | Cambridge, MA | 2 | $3.2 million | 0 | $0 |
| Nubad, LLC | Greer, SC | 1 | $3.2 million | 0 | $0 |
| Cornell University | Ithaca, NY | 4 | $3.1 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 4 | $3.1 million | 0 | $0 |
| University of Melbourne | Melbourne | 2 | $3.1 million | 0 | $0 |
| Celdara Medical, LLC | Lebanon, NH | 2 | $2.9 million | 0 | $0 |
| Northeastern University | Boston, MA | 1 | $2.9 million | 0 | $0 |
| Respana Therapeutics, Inc. | Philadelphia, PA | 2 | $2.8 million | 0 | $0 |
| Rand Corporation | Santa Monica, CA | 1 | $2.8 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 2 | $2.6 million | 0 | $0 |
| University of Nebraska-Lincoln | Lincoln, NE | 1 | $2.6 million | 0 | $0 |
| Pop Biotechnologies, INC | Buffalo, NY | 2 | $2.5 million | 0 | $0 |
| Princeton University | Princeton, NJ | 1 | $2.4 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 3 | $2.4 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 4 | $2.4 million | 0 | $0 |
| J. Craig Venter Institute, Inc. | La Jolla, CA | 1 | $2.3 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 325 | $326,081,366 | 0 | $0 |
| 2024 | 360 | $361,319,016 | 0 | $0 |
| 2023 | 364 | $391,139,831 | 0 | $0 |
| 2022 | 373 | $386,213,201 | 0 | $0 |
| 2021 | 375 | $421,081,437 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 4 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 499 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 499 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 499 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.